We are live on ! Find out more
ADMS

Adamas Pharmaceuticals
ADMS

Delisted

ADMS was delisted on the 23rd of November, 2021.

Back to rankings

79 hedge funds and large institutions have $62.1M invested in Adamas Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 31 increasing their positions, 19 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

214% more call options, than puts

Call options by funds: $1.41M | Put options by funds: $449K

63% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 19

9% less funds holding

Funds holding: 87 → 79 (-8)

16% less capital invested

Capital invested by funds: $74.3M → $62.1M (-$12.2M)

37% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 19

Holders
79
Holders Change
-8
Holders Change %
-9.2%
% of All Funds
1.56%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
12
Increased
31
Reduced
19
Closed
19
Calls
$1.41M
Puts
$449K
Net Calls
+$960K
Net Calls Change
+$885K

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$7.95M
2
SCM
Stonepine Capital Management
Oregon
+$7.13M
3
PAM
Panagora Asset Management
Massachusetts
+$1.3M
4
N
Nuveen
North Carolina
+$1.16M
5
Renaissance Technologies
Renaissance Technologies
New York
+$810K

Top Sellers

Rank Fund Capital Flow
1
Ameriprise
Ameriprise
Minnesota
-$3.6M
2
BlackRock
BlackRock
New York
-$2.3M
3
KA
Kerrisdale Advisers
Florida
-$1.17M
4
HVC
Healthcare Value Capital
New Jersey
-$957K
5
DAM
Deltec Asset Management
New York
-$844K
Name Holding Trade Value Shares
Change 		Change in
Stake
Russell Investments Group
76
Russell Investments Group
United Kingdom
$1K – – –
Fidelity Investments
77
Fidelity Investments
Massachusetts
$1K +$1.44K +300 New
APA
78
American Portfolios Advisors
New York
$569 – – –
KA
79
Kerrisdale Advisers
Florida
– -$1.17M -229,347 Closed
HVC
80
Healthcare Value Capital
New Jersey
– -$957K -200,000 Closed
BG
81
Bellevue Group
Switzerland
– -$593K -116,000 Closed
WVP
82
Worth Venture Partners
New Jersey
– -$396K -77,384 Closed
D.E. Shaw & Co
83
D.E. Shaw & Co
New York
– -$367K -71,724 Closed
DS
84
Dudley & Shanley
Florida
– -$345K -67,400 Closed
Two Sigma Investments
85
Two Sigma Investments
New York
– -$298K -58,231 Closed
BFM
86
Boothbay Fund Management
New York
– -$159K -31,000 Closed
PPA
87
Parametric Portfolio Associates
Washington
– -$111K -21,790 Closed
CS
88
Credit Suisse
Switzerland
– -$107K -20,995 Closed
WCM
89
Weld Capital Management
New York
– -$79K -15,376 Closed
HC
90
Henshaw Capital
Massachusetts
– -$53.4K -10,443 Closed
ProShare Advisors
91
ProShare Advisors
Maryland
– -$52K -10,090 Closed
QT
92
Quantamental Technologies
New York
– -$26K -5,101 Closed
TRCT
93
Tower Research Capital (TRC)
New York
– -$5K -1,007 Closed
MAM
94
Meeder Asset Management
Ohio
– -$5K -972 Closed
TC
95
Truvestments Capital
Florida
– -$2K -313 Closed
Daiwa Securities Group
96
Daiwa Securities Group
Japan
– -$1K -142 Closed
1 2 3
4

ADMS Hedge Fund Activity: Q4 2019 in Review

79 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q4 2019, worth a combined $62.1M — down 16% from $74.3M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of ADMS and 12 opened new positions — a net loss of 7 holders — while 19 trimmed existing stakes and 31 added.

The largest buyer was Armistice Capital, adding an estimated $7.95M. The largest seller was Ameriprise, cutting an estimated $3.6M.

  • 79 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q4 2019, down from 87 in Q3 2019.
  • Funds reported $62.1M of Adamas Pharmaceuticals stock for Q4 2019, down 16% quarter-over-quarter.
  • 12 funds opened new Adamas Pharmaceuticals positions in Q4 2019 and 19 closed out, a net change of -7 holders.
  • The largest Adamas Pharmaceuticals buyer in Q4 2019 was Armistice Capital, an estimated $7.95M added.
  • The largest Adamas Pharmaceuticals seller in Q4 2019 was Ameriprise, an estimated $3.6M sold.

Based on aggregated 13F filings for Q4 2019.